Bavarian Nordic A/S (BVNRY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bavarian Nordic A/S (BVNRY) with AI Score 50/100 (Hold). Bavarian Nordic A/S is a biotechnology company specializing in the development, manufacture, and commercialization of life-saving vaccines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Bavarian Nordic A/S (BVNRY) Healthcare & Pipeline Overview
Bavarian Nordic A/S is a commercial-stage biotechnology company focused on developing and commercializing vaccines for infectious diseases and cancer. With a diverse portfolio of approved vaccines and a pipeline of candidates in clinical trials, the company addresses critical unmet needs in global public health and oncology, operating across multiple international markets.
Investment Thesis
Bavarian Nordic presents a compelling investment case driven by its established portfolio of commercial vaccines and a promising pipeline of candidates. The company's revenue is supported by government contracts for smallpox and monkeypox vaccines, providing a stable base for future growth. The ongoing Phase III trials for MVA-BN RSV represent a significant catalyst, targeting a large market with substantial unmet needs. With a P/E ratio of 10.51 and a profit margin of 22.2%, the company demonstrates financial stability and profitability. However, investors may want to evaluate the risks associated with clinical trial outcomes and regulatory approvals, which could impact future revenue streams. The company's beta of 1.09 indicates market correlation.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.20 billion reflects investor confidence in Bavarian Nordic's vaccine portfolio and pipeline.
- P/E ratio of 10.51 suggests the company is undervalued compared to its earnings.
- Profit margin of 22.2% indicates strong profitability and efficient operations.
- Gross margin of 48.5% demonstrates the company's ability to maintain competitive pricing and manage production costs.
- The company's diverse vaccine portfolio, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines, provides multiple revenue streams and reduces reliance on a single product.
Competitors & Peers
Strengths
- Established portfolio of approved vaccines.
- Proprietary MVA-BN vaccine platform.
- Strong relationships with governments and public health organizations.
- Experienced management team.
Weaknesses
- Reliance on government contracts for revenue.
- Competition from larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- Limited geographic presence in some markets.
Catalysts
- Upcoming: Phase III clinical trial results for MVA-BN RSV vaccine expected in late 2026.
- Ongoing: Government contracts for smallpox and monkeypox vaccines provide a stable revenue stream.
- Ongoing: Development of new vaccines for emerging infectious diseases.
- Upcoming: Potential regulatory approvals for ABNCoV2 vaccine for SARS-CoV-2 in 2027.
- Ongoing: Expansion into new geographic markets.
Risks
- Potential: Clinical trial failures could negatively impact the company's pipeline and future revenue.
- Potential: Regulatory delays or rejections could delay the commercialization of new vaccines.
- Ongoing: Competition from larger pharmaceutical companies could erode market share.
- Potential: Changes in government funding priorities could reduce revenue from government contracts.
- Ongoing: Currency fluctuations could impact the value of the company's international sales.
Growth Opportunities
- MVA-BN RSV Vaccine: The MVA-BN RSV vaccine, currently in Phase III clinical trials, represents a significant growth opportunity for Bavarian Nordic. Respiratory syncytial virus (RSV) affects millions of people annually, particularly infants and the elderly, creating a substantial market for an effective vaccine. Successful completion of Phase III trials and subsequent regulatory approval could generate significant revenue streams, potentially reaching hundreds of millions of dollars annually, within the next 2-3 years. Bavarian Nordic's competitive advantage lies in its MVA-BN platform, which has demonstrated safety and efficacy in previous clinical trials.
- ABNCoV2 Vaccine: The ABNCoV2 vaccine, which has completed Phase II clinical trials for the treatment of SARS-CoV-2, offers a growth opportunity in the evolving market for COVID-19 vaccines. While the initial demand for COVID-19 vaccines has decreased, there remains a need for booster shots and vaccines that address emerging variants. If approved, ABNCoV2 could capture a share of this market, generating revenue in the tens of millions of dollars. The timeline for potential commercialization is dependent on further clinical trials and regulatory approvals, potentially within the next 1-2 years.
- TAEK-VAC Cancer Vaccine: The TAEK-VAC cancer vaccine, currently in Phase I/II clinical trials for the treatment of advanced HER2 and brachyury-expressing cancers, represents a long-term growth opportunity for Bavarian Nordic. The market for cancer vaccines is growing, driven by advances in immunotherapy and personalized medicine. Successful development and commercialization of TAEK-VAC could generate significant revenue, although the timeline is uncertain due to the early stage of clinical development. The potential market size could reach hundreds of millions of dollars annually, but commercialization is likely several years away.
- Geographic Expansion: Bavarian Nordic has the opportunity to expand its geographic presence, particularly in emerging markets where access to vaccines is limited. By partnering with local distributors and governments, the company can increase its sales and market share in these regions. This expansion could generate incremental revenue growth of 5-10% annually over the next 3-5 years. The company's existing infrastructure and expertise in vaccine development and manufacturing provide a competitive advantage in entering new markets.
- Government Contracts: Bavarian Nordic has a history of securing government contracts for its vaccines, particularly for smallpox and monkeypox. These contracts provide a stable revenue stream and support the company's research and development efforts. The company can continue to pursue government contracts for its existing vaccines and new vaccine candidates, ensuring a consistent source of funding and market access. The value of these contracts can range from tens to hundreds of millions of dollars annually, depending on the specific vaccine and the government's needs. Ongoing government preparedness initiatives for emerging infectious diseases will likely continue to drive demand.
Opportunities
- Expansion into emerging markets.
- Development of new vaccines for unmet medical needs.
- Strategic partnerships and collaborations.
- Increased government funding for vaccine research and development.
Threats
- Clinical trial failures.
- Regulatory delays or rejections.
- Competition from new vaccine technologies.
- Changes in government funding priorities.
Competitive Advantages
- Proprietary Vaccine Technology: Bavarian Nordic's MVA-BN platform provides a competitive advantage in developing safe and effective vaccines.
- Regulatory Expertise: The company has a strong track record of obtaining regulatory approvals for its vaccines.
- Government Relationships: Bavarian Nordic has established relationships with governments and public health organizations.
- Manufacturing Capabilities: The company has specialized manufacturing facilities for vaccine production.
About BVNRY
Bavarian Nordic A/S, founded in 1992 and headquartered in Hellerup, Denmark, is a biotechnology company dedicated to developing, manufacturing, and commercializing life-saving vaccines. The company's initial focus was on cancer vaccines, but it has since expanded to address infectious diseases. Bavarian Nordic's portfolio includes commercially available vaccines such as IMVAMUNE/IMVANEX/JYNNEOS for smallpox and monkeypox, Rabipur/RabAvert for rabies, Encepur for tick-borne encephalitis, and MVABEA for Ebola. These vaccines are distributed across the United States, Europe, and other international markets. The company is actively developing new vaccines, including MVA-BN RSV for respiratory syncytial virus, ABNCoV2 for SARS-CoV-2, and TAEK-VAC for advanced HER2 and brachyury-expressing cancers. Bavarian Nordic operates through strategic partnerships and collaborations, including license agreements with the National Cancer Institute and Public Health Service, to enhance its research and development efforts. The company's mission is to improve global health by providing innovative vaccines to prevent and treat life-threatening diseases.
What They Do
- Develops and manufactures vaccines for infectious diseases.
- Commercializes vaccines for smallpox and monkeypox under the names IMVAMUNE, IMVANEX, and JYNNEOS.
- Offers rabies vaccine for human use under the name Rabipur/RabAvert.
- Provides tick-borne encephalitis vaccine under the name Encepur.
- Manufactures Ebola vaccine under the name MVABEA.
- Conducts clinical trials for vaccines targeting respiratory syncytial virus (RSV), SARS-CoV-2, and certain cancers.
- Partners with organizations like the National Cancer Institute and Public Health Service for research and development.
Business Model
- Develops and manufactures vaccines.
- Sells vaccines to governments and healthcare providers.
- Generates revenue through commercial sales of approved vaccines.
- Receives funding through government contracts and grants.
- Out-licenses vaccine technology and collaborates with other companies.
Industry Context
Bavarian Nordic operates within the global biotechnology industry, which is characterized by intense research and development, regulatory scrutiny, and high growth potential. The market for vaccines is expanding due to increasing awareness of preventative healthcare and government initiatives to combat infectious diseases. The company competes with established pharmaceutical giants and specialized biotechnology firms. Bavarian Nordic's focus on developing and commercializing vaccines for both common and rare diseases positions it as a key player in the global vaccine market.
Key Customers
- Governments: Purchase vaccines for national stockpiles and public health programs.
- Healthcare Providers: Administer vaccines to patients in hospitals and clinics.
- International Organizations: Procure vaccines for global health initiatives.
- Military Organizations: Acquire vaccines to protect personnel from infectious diseases.
Financials
Chart & Info
Bavarian Nordic A/S (BVNRY) stock price: Price data unavailable
Latest News
No recent news available for BVNRY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BVNRY.
Price Targets
Wall Street price target analysis for BVNRY.
MoonshotScore
What does this score mean?
The MoonshotScore rates BVNRY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul John Chaplin
President and Chief Executive Officer
Paul Chaplin has served as the President and Chief Executive Officer of Bavarian Nordic since 2011. Prior to joining Bavarian Nordic, he held various leadership positions in the pharmaceutical industry, including roles at GlaxoSmithKline and Corixa Corporation. Chaplin has extensive experience in vaccine development, manufacturing, and commercialization. He holds a Ph.D. in Molecular Biology from the University of Edinburgh.
Track Record: Under Paul Chaplin's leadership, Bavarian Nordic has transformed from a small research company into a global vaccine company with a diverse portfolio of approved vaccines and a promising pipeline of candidates. He has overseen the successful development and commercialization of key vaccines, including IMVAMUNE/IMVANEX/JYNNEOS and Rabipur/RabAvert. Chaplin has also led the company's strategic expansion into new markets and therapeutic areas.
Bavarian Nordic A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. BVNRY is an unsponsored Level 1 ADR, meaning it trades over-the-counter (OTC) without direct involvement from Bavarian Nordic. It allows US investors to invest in BVNR (Bavarian Nordic A/S) without dealing with foreign exchanges.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BVNR
BVNRY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bavarian Nordic (BVNRY) has limited or no reporting requirements with U.S. regulators. Companies in this tier may not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for limited information availability.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: Lack of regular financial reporting increases the risk of investing in BVNRY.
- Illiquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Price Volatility: OTC stocks are often more volatile than stocks listed on major exchanges.
- Potential for Fraud: The lack of regulatory oversight increases the risk of fraudulent activity.
- Information Asymmetry: Limited information availability can put investors at a disadvantage.
- Verify the company's registration and legal status.
- Research the company's management team and their track record.
- Obtain and review any available financial information.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Established Business Operations: Bavarian Nordic has a history of developing and commercializing vaccines.
- Partnerships with Reputable Organizations: The company has collaborations with government agencies and research institutions.
- Presence in Multiple Markets: Bavarian Nordic operates in the United States, Europe, and other international markets.
- FDA-Approved Products: The company has several FDA-approved vaccines in its portfolio.
- Experienced Leadership: The company is led by an experienced management team with a track record in the pharmaceutical industry.
Bavarian Nordic A/S Stock: Key Questions Answered
What does Bavarian Nordic A/S do?
Bavarian Nordic A/S is a biotechnology company focused on developing, manufacturing, and commercializing life-saving vaccines. Its core business revolves around creating vaccines for infectious diseases, including smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola. The company generates revenue through the sale of these vaccines to governments, healthcare providers, and international organizations. Bavarian Nordic also invests in research and development to expand its vaccine pipeline and address emerging health threats, positioning itself as a key player in global public health.
What do analysts say about BVNRY stock?
Analyst coverage of BVNRY is limited due to its OTC listing. However, based on available information, analysts generally view Bavarian Nordic favorably due to its established vaccine portfolio and promising pipeline. Key valuation metrics include the company's P/E ratio of 10.51 and profit margin of 22.2%. Growth considerations include the potential for new vaccine approvals and expansion into emerging markets. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for BVNRY?
The main risks for Bavarian Nordic include clinical trial failures, regulatory delays, competition from larger pharmaceutical companies, and changes in government funding priorities. Clinical trial failures could negatively impact the company's pipeline and future revenue. Regulatory delays or rejections could delay the commercialization of new vaccines. Competition from larger pharmaceutical companies could erode market share. Changes in government funding priorities could reduce revenue from government contracts. Additionally, as an ADR traded OTC, BVNRY faces risks related to currency fluctuations and limited liquidity.
What are the key factors to evaluate for BVNRY?
Bavarian Nordic A/S (BVNRY) currently holds an AI score of 50/100, indicating moderate score. Key strength: Established portfolio of approved vaccines.. Primary risk to monitor: Potential: Clinical trial failures could negatively impact the company's pipeline and future revenue.. This is not financial advice.
How frequently does BVNRY data refresh on this page?
BVNRY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BVNRY's recent stock price performance?
Recent price movement in Bavarian Nordic A/S (BVNRY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established portfolio of approved vaccines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BVNRY overvalued or undervalued right now?
Determining whether Bavarian Nordic A/S (BVNRY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BVNRY?
Before investing in Bavarian Nordic A/S (BVNRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.